Today: 4 March 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Linde (LIN) Stock After Hours on December 9, 2025: 52‑Week Lows, CEO Buying, and What to Watch Before the December 10 Open

Linde (LIN) Stock After Hours on December 9, 2025: 52‑Week Lows, CEO Buying, and What to Watch Before the December 10 Open

Linde shares closed at $390.38 on December 9, up 0.26% after a sharp sell-off, but slipped to $389.35 in after-hours trading. The stock is near its 52-week low of $387.78 and trades about 7% below its 2025 starting price, despite strong earnings. CEO recently bought nearly $1 million in shares. Wall Street projects about 30% upside over the next year.
10 December 2025
·
Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma shares fell 4.2% to around $197.25 in late trading December 9 after a Q3 earnings miss and a three-month FDA review delay for its key dwarfism drug. Volume was about 76% below average. The company posted Q3 revenue of €213.6 million but reported a net loss of €61 million, mainly from finance expenses. Despite the pullback, ASND remains near its 52-week high and up year-on-year.
9 December 2025
··
KE Holdings (BEKE) Stock Slides as Buybacks Accelerate: What Q3 2025 Earnings and China’s Housing Slump Mean for Investors

KE Holdings (BEKE) Stock Slides as Buybacks Accelerate: What Q3 2025 Earnings and China’s Housing Slump Mean for Investors

KE Holdings (NYSE: BEKE) shares fell about 4.8% Tuesday, opening near $16.35 after closing at $17.08, with over 1 million shares traded. The drop came despite ongoing share buybacks and Q3 revenue rising 2.1% year-on-year to RMB 23.1 billion. Net income fell to RMB 747 million from RMB 1.17 billion a year earlier. BEKE underperformed even as international ETF VXUS saw strong inflows.
9 December 2025
····
O’Reilly Automotive (ORLY) Stock Outlook: Institutional Buying, Q3 Beat and 2026 Growth Drivers as of December 9, 2025

O’Reilly Automotive (ORLY) Stock Outlook: Institutional Buying, Q3 Beat and 2026 Growth Drivers as of December 9, 2025

O’Reilly Automotive shares fell 3.9% to $94.31 on December 9, 2025, with trading volume near 5 million, following a recent stock split. Multiple large institutional investors disclosed sharply increased stakes. Third-quarter results showed 5.6% same-store sales growth and a 12% rise in diluted EPS to $0.85, beating estimates. Management raised the lower end of 2025 revenue guidance.
9 December 2025
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics shares traded at $17–18 on December 9, 2025, near the low end of their 52-week range of $15.55 to $36.91. The company’s lung cancer drug ivonescimab recently outperformed Keytruda in a limited trial, drawing attention but also regulatory questions. Summit granted inducement stock options to new hires on December 5. The company’s market cap stands near $13–14 billion.
9 December 2025
·
Credo Technology Group (CRDO) Stock: Earnings Blowout, AI Tailwinds, and What Comes Next

Credo Technology Group (CRDO) Stock: Earnings Blowout, AI Tailwinds, and What Comes Next

Credo Technology Group shares traded near $169 on December 9, 2025, down from a record $213.80 hit a week earlier after strong earnings. The company reported Q2 fiscal 2026 revenue of $268 million, far above estimates, and net income of $82.6 million versus a loss last year. Management raised Q3 guidance to $335–$345 million in revenue, citing demand from AI data centers.
9 December 2025
···
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.
9 December 2025
··
Ferguson Enterprises (FERG) Stock Slides After Q1 2026 Earnings – What Today’s Sell-Off Means for Investors

Ferguson Enterprises (FERG) Stock Slides After Q1 2026 Earnings – What Today’s Sell-Off Means for Investors

Ferguson Enterprises reported Q1 net sales of $8.17–8.2 billion, up 5.1% year-on-year, and adjusted diluted EPS of $2.84, up 15.9%. Shares fell sharply despite raised full-year guidance, as investors weighed valuations and growth forecasts. Residential revenue slipped 1%, while non-residential revenue jumped 12% on strong commercial demand. The company now targets 5% net sales growth for 2025.
9 December 2025
···
Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging shares fell to a new 52-week low near $14 on December 9, 2025, after the company cut its full-year earnings outlook and announced cost and production optimization measures. Trading volume topped 10 million shares. The company also confirmed a CEO transition for early 2026. Net sales guidance remains at $8.4–$8.6 billion.
9 December 2025
··
SLM Stock Plunges Over 16% After Investor Day: New EPS Targets, Analyst Downgrades and 2026–2028 Outlook for Sallie Mae (SLM)

SLM Stock Plunges Over 16% After Investor Day: New EPS Targets, Analyst Downgrades and 2026–2028 Outlook for Sallie Mae (SLM)

SLM Corporation shares plunged 16–17% to about $25.85 on December 9 after its Investor Forum revealed sharply lower earnings guidance for 2026 and 2027. Management projected FY26 EPS of $2.63, about 23% below prior consensus, and signaled higher operating expenses tied to a strategic shift. Trading volume was several times normal. The stock now trades just above its 52-week low.
9 December 2025
·
Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems shares traded at $141.72 on December 9, 2025, after a volatile year that included a 21% surge two weeks prior following an analyst upgrade and positive reimbursement news. Q3 revenue rose 10% to $224.5 million, with net income at $9.9 million and adjusted EPS of $0.38, beating estimates. The company also launched its new Inspire 5 system.
9 December 2025
·
Kontoor Brands (KTB) Stock on December 9, 2025: Q3 Beat, Analyst Upgrades and Volatile Trading Create a 2026 Upside Story

Kontoor Brands (KTB) Stock on December 9, 2025: Q3 Beat, Analyst Upgrades and Volatile Trading Create a 2026 Upside Story

Kontoor Brands shares traded between $75 and $76 on December 9, about 19% below their January high, after falling 3–4% intraday amid weak consumer data. Wells Fargo raised its price target to $100 and reiterated an “overweight” rating. Marshall Wace trimmed its stake following recent gains. Kontoor’s Q3 revenue rose 27% to $853 million, with EPS of $1.44 beating forecasts.
9 December 2025
··
AutoZone (AZO) Stock Plunges After Q1 2026 Earnings Miss — What Investors Need to Know Today

AutoZone (AZO) Stock Plunges After Q1 2026 Earnings Miss — What Investors Need to Know Today

AutoZone shares fell about 7–8% Tuesday after fiscal Q1 2026 results missed profit estimates, making it the S&P 500’s worst performer. Net sales rose 8.2% to $4.63 billion, but net income dropped to $530.8 million from $564.9 million a year earlier. Diluted EPS came in at $31.04, below analyst forecasts and marking a sixth straight quarterly miss. Trading volume surged as investors reacted to weaker margins and guidance.
9 December 2025
··
D-Wave Quantum (QBTS) Stock in December 2025: Rally, Volatility, and What Analysts Expect Next

D-Wave Quantum (QBTS) Stock in December 2025: Rally, Volatility, and What Analysts Expect Next

D-Wave Quantum shares traded at $27–28 on December 9, 2025, up over 200% year to date after sharp swings. The stock plunged nearly 40% in November before rebounding more than 20% in early December, driven by bullish analyst coverage and renewed investor interest. Evercore ISI initiated coverage with an “Outperform” rating and a $44 target. Institutional investors have increased positions as volatility remains high.
9 December 2025
···
Hawaiian Electric Industries (HE) Stock Soars on S&P 600 Inclusion – Latest News, Maui Settlement Update and 2026 Forecasts

Hawaiian Electric Industries (HE) Stock Soars on S&P 600 Inclusion – Latest News, Maui Settlement Update and 2026 Forecasts

Hawaiian Electric Industries stock surged over 11% on December 8, 2025, after S&P Dow Jones Indices announced its addition to the S&P SmallCap 600. Shares traded near $11.73 on December 9, with market cap at $2.1 billion. The move follows a year of legal pressure from Maui wildfire settlements, with analysts maintaining a “Hold” rating. Trading volume spiked to 1.4 million shares, well above normal levels.
9 December 2025
··
1 … 496 497 498 499 500 … 584
Go toTop